Infectious Disease · AntibioticRegulatory Approvalcommercialnear-term

FDA Grants Approval for Cefixime ANDA218691 by FDC LTD

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/16/2026, 6:31:33 PM

Assessment confidence: 53% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's approval of FDC LTD's generic Cefixime introduces significant competition in the antibiotic market, which could impact pricing and market share for existing branded products. Portfolio teams must evaluate the implications for their strategies in response to this new market entrant. Regulatory context from FDA (FDA AP — CEFIXIME (ORIG)) supports the near-term read. Assessment grounded in 19 ranked evidence items (3 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing Cefixime products. The strongest clinical anchor is Genetic Studies of Chronic Active Epstein-Barr Disease (ClinicalTrials.gov), moderate corpus alignment. In Infectious Disease · Antibiotic, 3 regulatory and 4 competitive items passed relevance filtering for FDC LTD.

Competitive Pressure

The most relevant competitive pressure comes from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Grants Priority Review for ZERBAXA Supplement by Cubist Pharmaceuticals. This approval allows FDC LTD to enter the market with a generic version of Cefixime, potentially increasing competition against branded formulations.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — CEFIXIME (ORIG) (FDA). Entity match (fdc ltd); Regulatory pathway relevance (nda). The approval indicates compliance with FDA standards, but does not suggest immediate regulatory challenges for existing products.

Key Opportunities

The entry of a generic version of Cefixime may lead to price reductions and a shift in market share, affecting revenue for current branded formulations.
Upside for FDC LTD may improve if Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV (ClinicalTrials.gov) delivers favorable follow-through.
Lead sponsor: Bausch & Lomb Incorporated.
Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing Cefixime products.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and pricing strategies from FDC LTD and competitors.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
Outcome from Rare Disease Drug Approvals would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — CEFIXIME (ORIG)
FDAhigh relevance
Entity match (fdc ltd); Regulatory pathway relevance (nda)
FDA document
View source
Rare Disease Drug Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source

Genetic Studies of Chronic Active Epstein-Barr Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
LASER VERSUS CRYSTALLIZED PHENOL IN PILONIDAL SINUS DISEASE
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study Evaluating the Safety and Efficacy of Fixed-Dose Combination for Dry Eye Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for ZERBAXA Supplement by Cubist Pharmaceuticals
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Veklury as First Treatment for COVID-19
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for LEQEMBI Supplement Application
Humanexa Signalsmedium relevance
Moderate corpus alignment

RNA polymerase II phosphorylation dynamics: from molecular mechanisms to human disease.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lactiplantibacillus plantarum (WJL) ameliorates chronic kidney disease by inhibiting fibroblast growth factor 21 adaptive stress response via low protein diet.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Compliance with preoperative antibiotic prophylaxis in cesarean delivery and its impact on surgical site infections: A national retrospective study of Jordan.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

FDC LTD
Cefixime

Commercial impact

medium

The entry of a generic version of Cefixime may lead to price reductions and a shift in market share, affecting revenue for current branded formulations.

Regulatory impact

low

The approval indicates compliance with FDA standards, but does not suggest immediate regulatory challenges for existing products.

What to watch

Monitor market entry timelines and pricing strategies from FDC LTD and competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.